The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP)

The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) is a strategic venture philanthropy initiative that seeks to accelerate the development of innovative blood cancer therapeutics and change the standard of care. LLS TAP collaborates with biotech companies to support the development of novel platforms, first-in-class assets addressing unmet medical needs, emerging patient populations and even rare blood cancers. TAP funds late-stage preclinical studies, and proof of concept or registrational clinical trials to help advance therapeutics along the drug development and approval pathway. LLS TAP makes individual investments of up to approximately $10 million and offers insights to funded companies from its extensive knowledge of blood cancer indications, the treatment landscape, and the expertise of LLS staff.